5 unchanged sentences
Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.
−Removed: During the third quarter of 2025, none of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
−Removed: Indenture (including form of Note) with respect to the Company’s 9.00% Convertible Senior Notes due 2028, dated October 10, 2025,between the Company, the guarantors party thereto and Wilmington Savings Fund Society, FSB, as trustee and collateral agent (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-36167) filed with the SEC on October 14, 2025).
−Removed: Indenture (including form of Note) with respect to the Company’s 9.00% Convertible Senior Notes due 2029, dated October 10, 2025,between the Company, the guarantors party thereto and Wilmington Savings Fund Society, FSB, as trustee and collateral agent (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-36167) filed with the SEC on October 14, 2025).
−Removed: Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.3 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-36167) filed with the SEC on October 14, 2025).
−Removed: Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.4 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-36167) filed with the SEC on October 14, 2025).
−Removed: Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.5 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-36167) filed with the SEC on October 14, 2025).
−Removed: Form of Pre-Funded Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.6 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-36167) filed with the SEC on October 14, 2025).
−Removed: First Amendment and Waiver to Credit and Guaranty Agreement, dated October 7, 2025, by and among the Company, as borrower, the lenders party thereto and Wilmington Savings Fund Society, FSB, as administrative agent for the lenders party thereto and collateral agent (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-36167) filed with the SEC on October 14, 2025).
−Removed: Note Purchase Agreement, dated October 7, 2025, by and among the Company and the other parties thereto (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-36167) filed with the SEC on October 14, 2025).
−Removed: Form of Exchange Agreement, dated October 7, 2025, by and among the Company and the other parties thereto (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-36167) filed with the SEC on October 14, 2025).
−Removed: Form of Exchange Agreement, dated October 7, 2025, by and among the Company and the other parties thereto (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-36167) filed with the SEC on October 14, 2025).
−Removed: Form of Exchange Agreement, dated October 7, 2025, by and among the Company and the other parties thereto (incorporated by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-36167) filed with the SEC on October 14, 2025).
−Removed: Sixth Amendment to the Revenue Interest Financing Agreement, dated October 7, 2025, by and among the Company and the investors party thereto, HealthCare Royalty Management, LLC as the investor representative, and HCR Karyopharm SPV, LLC, as the collateral agent (incorporated by reference to Exhibit 10.6 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-36167) filed with the SEC on October 14, 2025).
−Removed: Securities Purchase Agreement, dated October 7, 2025, by and among the Company and the other parties thereto (incorporated by reference to Exhibit 10.7 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-36167) filed with the SEC on October 14, 2025).
−Removed: Form of Registration Rights Agreement, dated October 10, 2025, by and among the Company and the other parties thereto (incorporated by reference to Exhibit 10.8 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-36167) filed with the SEC on October 14, 2025).
−Removed: Registration Rights Agreement, dated October 7, 2025, by and among the Company and the other parties thereto (incorporated by reference to Exhibit 10.9 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-36167) filed with the SEC on October 14, 2025).
−Removed: Third Amendment to Revenue Interest Financing Agreement, dated as of August 14, 2025 by and among Karyopharm Therapeutics Inc., Healthcare Royalty Partners III, L.P., Healthcare Royalty Partners IV, L.P., HCRX Investments Holdco, LLC, HCR Canary Fund, L.P., HCR Molag Fund, L.P., Healthcare Royalty Management, LLC and HCR Karyopharm SPV, LLC.
−Removed: Fourth Amendment to Revenue Interest Financing Agreement, dated as of August 27, 2025 by and among Karyopharm Therapeutics Inc., Healthcare Royalty Partners III, L.P., Healthcare Royalty Partners IV, L.P., HCRX Investments Holdco, LLC, HCR Canary Fund, L.P., HCR Molag Fund, L.P., Healthcare Royalty Management, LLC and HCR Karyopharm SPV, LLC.
−Removed: Amendment No.
−Removed: 4 to License Agreement, dated August 7, 2025, by and between the Registrant and Berlin-Chemie AG.
+Added: During the first quarter of 2026, none of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K).
+Added: Restated Certificate of Incorporation of the Registrant, as amended
+Added: Pre-Funded Warrant to Purchase Common Stock, dated March 26, 2026, by and between the Registrant and RA Capital Management.
+Added: Warrant to Purchase Common Stock dated March 26, 2026, by and between the Registrant and RA Capital Management.
+Added: Second Amendment to Credit and Guaranty Agreement, dated February 27, 2026 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-36167) filed with the SEC on March 3, 2026).
+Added: Securities Purchase Agreement, dated March 24, 2026, by and between the Company and RA Capital Management (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-36167) filed with the SEC on March 24, 2026).
+Added: Registration Rights Agreement, dated March 26, 2026, by and between the Company and RA Capital Management.
Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.
8 unchanged sentences
Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)
+Added: * Certain exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KARYOPHARM THERAPEUTICS INC.
−Removed: November 3, 2025
/s/ Richard Paulson
2 unchanged sentences
(Principal executive officer)
−Removed: November 3, 2025
/s/ Lori Macomber
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.